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51%, matched-unrelated (40%), or mismatched related (9%). 41
patients (47%) received PBSC and 45 patients (51%) received
BMSC. Only 2 patients received cord blood transplant. GVHD
prophylaxis was tacrolimus (89%) or cyclosporine-based (10%) in
89% and 1. Predictors of NRM and disease progression at one year
post HSCT were evaluated using Cox’s proportional hazards
model for univariate and multivariate analysis. Results: 29 of 88
patients are alive with median follow-up 22 months (1-143). Ac-
tuarial estimate of survival at 2 yrs was 29%. Cumulative incidence
of progression was 24% and NRM 47% at 2 yrs. Donor type and
preparative regimen were signiﬁcant predictors of NRM on mul-
tivariate analysis (Table 1). There was a trend for an increased rate
of progression among patients with high risk IPSS (HR  3.8), yet
this did not reach statistical signiﬁcance (P  .06). None of the
other factors evaluated had an impact on the rate of progression.
Conclusion: Allogeneic HSCT can provide long-term disease
control for a signiﬁcant proportion of patients with MDS. These
results suggest that Flu/Bu may provide optimal cytoreduction
with lower toxicity. Progression and late deaths from GVHD
remain a signiﬁcant problem. Strategies aimed at addressing these
issues are currently in development (Table 1).
Table 1. Predictors of NRM and Progression within 1 yr post
Allogeneic HSCT: Univariate Analysis
Variable
NRM Progression
N HR
95%
CI
P
Value HR
95%
CI
P
Value
IC
Yes 30 0.6 0.3–1.2 .20 1.8 0.7–4.6 .20
No 58 Ref. — — Ref. — —
Age
<50 43 Ref. — — Ref. — —
>50 45 0.9 0.5–1.8 .80 1.2 0.4–2.9 .80
IPSS
Low 4 0.2 0.03–1.7 .15 *Excluded — —
Intermediate 1 25 0.6 0.3–1.3 .20 Ref. — —
Intermediate 2 35 0.3 0.14–0.7 .01 1.2 0.3–4.7 .80
High risk 24 Ref. — — 3.8 0.97–14.7 .06
Regimen
Myeloablative 27 0.8 0.4–1.6 .50 0.6 0.1–2.4 .50
ID 01-011 (Blu/Flu) 26 0.1 0.02–0.4 .004 1.3 0.4–3.8 .60
Reduced intensity 35 Ref. — — Ref. — —
Allotype
Matched sibling 45 Ref. — — Ref. — —
Mismatched sibling 8 2.7 0.9–8.4 .90 3.3 0.8–11.3 .09
Unrelated 35 2.8 1.4–5.9 .005 1.15 0.4–3.4 .80
*Excluded because of small number.
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Uncertainty still exists with the effects of allo PBSCT on the out-
come of patients with hematological malignancies. Our aim was an-
alyzed retrospectively 151 AML patients with HLA identical sibling
donors who underwent an allo PBSCT. Median age was 32 (3-64),
and advanced disease was present in 68%; GVHD prophylaxis used
was MTX/CsA in 95%; CD34 median was 3.74  106/kg (1.2-24);
the median follow-up for surviving patients was 33 mo (0.6-86);
median day for neutrophils and platelets engraftment was 15 and 14;
in univariate analyses early disease and CD34 cell dose 	3.7 
106/kg were associated with faster neutrophil engraftment, and early
disease for platelet engraftment. CI for  2 aGVHD was 34%;
extensive cGVHD 65%; however, extensive cGVHD was 58% for
other than female donors for male recipients (P  .02). OS and DFS
at 86 mo was 39% and 53%; factors associated with better OS in
univariate analyses were early disease (61%) (P  .02), no TBI con-
ditioning (41%) (P  .02), and presence of extensive cGVHD (58%)
(P  .001). Furthermore, DFS for early disease was 73% (P  .003);
and for extensive cGVHDpatients 75% (P .001). CI for relapse was
47%; but in patients with early disease it was 23% (P .001), and with
cGVHD 26% (P  .001). CI for TRM was 46%; TRM for no
aGVHDwas 20% (P .03). In multivariate analyses female donor for
male recipient had a negative impact on neutrophil engraftment (P
.03), and early disease was related with faster neutrophil and platelet
engraftment (P  .02, P  .05); female donor for male recipient was
associated with more cGVHD (P  .02); early disease was predictive
of improved OS (P  .03) and DFS (P  .01), and TBI conditioning
and no cGVHD with worst OS (P  .01, P  .001) and DFS (P 
.001, P  .001); early disease was associated with fewer relapses (P 
.01), and no cGVHD with higher relapses (P .001); aGVHD had a
positive impact on TRM (P  .03). In AML the allo PBPCT seems
to be associated with leukemia control and DFS beneﬁt.
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We evaluated the outcome of reduced-intensity (RI) condition-
ing followed by allogeneic hematopoietic stem cell transplantation
(HSCT) in 31 patients with MDS who were not eligible for a
standard myeloablative-conditioning regimen. All 31 patients re-
ceived ﬂudarabine 125 mg/m2 plus melphalan 140 mg/m2 followed
by an allogeneic HSCT (blood stem cell: n  28, bone marrow:
n  3) from an HLA-identical sibling (SIB: n  15) or unrelated
donor (MUD: n  16). GVHD prophylaxis was cyclosporine
(CSP)  mycophenolate (MMF) (n  12) or FK-506  sirolimus
(n  2) or FK-506  methotrexate (MTX)  sirolimus (n  1) for
sibling donor transplants; and CSP  MMF  MTX (n  9), or
CSP  MMF (n  6) or FK-506  MMF  MTX (n  1), for
unrelated donor transplants. Median age was 53 years (range 32-
74). Ten patients had prior autologous HSCT. Diagnoses at time
of transplantation were RA (n 8), RARS (n 2), RAEB (n 15),
and RAEB-T (n  6). By IPSS criteria, 2 patients had low, 11 had
intermediate 1, 10 had intermediate 2, and 8 had high-risk MDS.
All patients engrafted with the median neutrophil recovery at day
15 (range: 9-24). After follow up of 20 months (median: range:
11-54 mo), 15 patients were alive. The 2-year actuarial overall
survival (OS), disease-free survival (DFS), relapse, and transplant-
related mortality (TRM) were 53.9% (CI: 43.8-63.0), 48.4% (CI:
38.8-57.3), 28.6% (CI: 16.2-47.4), and 24.7% (CI: 14.9-39.2) re-
spectively. Of 31 patients, grade II to IV acute GVHD occurred in
18 patients and grade III to IV in 11 patients. Twenty of 28
evaluable patients had chronic GVHD. There was no signiﬁcant
survival difference between related and unrelated donor HSCT
(SIB 42.7% vs. MUD 62.5%, P  .60). In univariate analysis,
higher IPSS or older age, or prior auto-SCT was not signiﬁcantly
associated with poor survival. Acute GVHD grade III-IV was
associated with higher TRM (HR  7.5; P  .01) and lower OS
(HR 3.3; P  .02). In summary, RI-HSCT was associated with
acceptable toxicity; and survival rate was comparable or superior to
full-intensity HSCT in this high-risk cohort.
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